FIG 3.

Immunogenicity of WNV-ΔNS1. (A and B) PRNT₅₀ assay. PRNT₅₀ testing against both WT WNV and WNV-ΔNS1 was performed with two different neutralizing antibodies against WNV envelope, i.e., FD011-1 (A) and FD011-2 (B). Serial 2-fold dilutions of neutralizing antibodies were incubated with WT WNV or WNV-ΔNS1 viruses. The inhibition rates were calculated by defining no-antibody treatment of WT WNV (0 μg/ml) as 0%. (C) ELISA of the antisera against WNV and WNV-ΔNS1. Two independent experiments were performed in triplicate. Data represent the mean ± standard deviation of triplicate measurements in a representative experiment. The asterisks denote statistical differences between the indicated groups. *, P < 0.05; **, P < 0.01; n.s., no statistical difference.